Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study-Reference-Cited by-同舟云学术

Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort study

Published:2023-01 Issue: Volume:206 Page:107058
ISSN:0954-6111
Container-title:Respiratory Medicine
language:en
Short-container-title:Respiratory Medicine

Author:

Thelen John C.,van Zelst Cathelijne M.,van Brummelen Sigrid E.^ORCID,Rauh Simone^ORCID,in ’t Veen Johannes C.C.M.^ORCID,Kappen Jasper H.^ORCID,Braunstahl Gert-Jan^ORCID

Funder

Sanofi Genzyme

Sanofi

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference23 articles.

1. The prevalence of severe refractory asthma;Hekking;J. Allergy Clin. Immunol.,2015

2. The prevalence of subtypes of type 2 inflammation in an unselected population of patients with severe asthma;Frøssing;J. Allergy Clin. Immunol. Pract.,2021

3. The prevalence and clinical characteristics of T2-high and T2-low endotype of severe uncontrolled asthma distinguished by combining popular type-2 biomarkers;Oishi;Eur. Respir. J.,2019

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dupilumab responder types and predicting factors in patients with type 2 severe asthma: A real-world cohort study;Respiratory Medicine;2024-09

2. Predicting dupilumab effectiveness with Type-2 biomarkers: A real-world study of severe asthma;Allergology International;2024-09

4. A real-world study of symptomatic eosinophilia in moderate-to-severe asthma patients on dupilumab therapy;The Journal of Allergy and Clinical Immunology: In Practice;2024-08

5. Higher prevalence of dupilumab‐induced ocular adverse events in atopic dermatitis compared to asthma: A daily practice analysis;Clinical and Translational Allergy;2024-08